Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA — Investor Relations & Filings

Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,398 across all filing types
Latest filing 2019-11-20 Investor Presentation
Country DE Germany
Listing F FRE

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Roadshow Sydney
Investor Presentation Classification · 99% confidence The document text contains multiple references to specific financial periods, such as 'Q3/19 Highlights', 'Q3/19 Key Financials', and forward-looking guidance for '2020 - 2023'. It details segment performance (Fresenius Kabi, Helios, Vamed) with key metrics like sales, EBIT, and organic growth rates. The structure, content (financial tables, segment updates, outlook), and explicit mention of a quarterly period ('Q3/19') strongly indicate this is a comprehensive report covering recent performance, which aligns with the definition of an Interim/Quarterly Report (IR). It is too detailed to be just an Earnings Release (ER) and is not a full annual report (10-K).
2019-11-20 English
Roadshow Singapur
Investor Presentation Classification · 98% confidence The document is titled "Roadshow Singapore" and contains extensive slides detailing the company's business segments (Fresenius Medical Care, Kabi, Helios, Vamed), market dynamics, growth drivers, capital deployment strategy, and specific financial highlights for Q3/19. The content structure, including slides on TSR, segment updates, and detailed financial tables comparing Q3/19 reported figures to prior periods, is characteristic of an Investor Presentation (IP) or a management presentation delivered during an investor event (like a roadshow). It is not a formal regulatory filing like a 10-K, nor is it a short announcement (RPA/RNS). It is a detailed presentation aimed at investors.
2019-11-19 English
Bryan, Garnier & Co. European Healthcare Conference
Investor Presentation Classification · 98% confidence The document text is a presentation slide deck, indicated by the structure (headings, bullet points, tables summarizing data) and the context provided in the title: "Bryan Garnier European Healthcare Conference". It contains financial highlights, segment updates (Fresenius Kabi, Helios, Vamed), and forward-looking statements, specifically referencing Q3/19 results and confirming guidance. This format strongly suggests an Investor Presentation (IP) used to communicate performance and strategy to investors, rather than a formal regulatory filing like a 10-K or a standalone Earnings Release (ER) which is usually a press release summary. The length (28,783 chars) is substantial, ruling out a simple RPA/RNS, and the content is detailed, fitting the IP definition.
2019-11-12 English
HSBC European Healthcare Day
Investor Presentation Classification · 99% confidence The document text contains multiple references to specific financial periods, such as 'Frankfurt, 11 November 2019', 'Q3/19 Highlights', 'Q3/19 Key Financials', and 'Fresenius Group: Healthy Growth Targets 2020 - 2023'. The content is highly detailed, covering segment performance (Fresenius Kabi, Helios, Vamed), key financial metrics (Sales, EBIT, Margin), and outlook updates for the upcoming periods. This structure is characteristic of a comprehensive quarterly financial report, which aligns with the definition of an Interim / Quarterly Report (IR). It is not a brief announcement (RPA/ER) nor the full annual report (10-K).
2019-11-11 English
Roadshow Tel Aviv
Investor Presentation Classification · 99% confidence The document text contains slides from a presentation, specifically mentioning 'Roadshow Tel Aviv' dated November 07, 2019, and includes a 'Financial Review Q3/19' section with key financial highlights and segment updates (Fresenius Kabi, Helios, Vamed, Medical Care). The content is strategic, operational, and financial, presented in a slide deck format, which strongly indicates an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K or an Earnings Release (ER) which typically contains structured financial statements or press release text, nor is it a short announcement about a report (RPA/RNS).
2019-11-07 English
Roadshow London
Investor Presentation Classification · 99% confidence The document text is clearly a presentation, indicated by the title 'Roadshow London', the presence of 'Safe Harbor Statement', numerous slides/page breaks indicated by image placeholders, and sections detailing business segments (Fresenius Medical Care, Kabi, Helios, Vamed) along with financial highlights for a specific period ('Financial Review Q3/19', 'Q3/19 Highlights'). This structure is characteristic of an Investor Presentation (IP), which is used to communicate strategy, performance, and outlook to investors, often during roadshows or investor days. It is not a formal regulatory filing like a 10-K or a brief announcement like an ER or RPA.
2019-11-04 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.